<?xml version='1.0' encoding='utf-8'?>
<document id="17195945"><sentence text="Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers."><entity charOffset="43-53" id="DDI-PubMed.17195945.s1.e0" text="irinotecan" /><entity charOffset="63-75" id="DDI-PubMed.17195945.s1.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.17195945.s1.e0" e2="DDI-PubMed.17195945.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17195945.s1.e0" e2="DDI-PubMed.17195945.s1.e1" /></sentence><sentence text="Capecitabine and irinotecan have demonstrated in vitro synergistic anti-cancer activity, and both are substrates for carboxyl esterases (CES)"><entity charOffset="0-12" id="DDI-PubMed.17195945.s2.e0" text="Capecitabine" /><entity charOffset="17-27" id="DDI-PubMed.17195945.s2.e1" text="irinotecan" /><entity charOffset="117-125" id="DDI-PubMed.17195945.s2.e2" text="carboxyl" /><pair ddi="false" e1="DDI-PubMed.17195945.s2.e0" e2="DDI-PubMed.17195945.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17195945.s2.e0" e2="DDI-PubMed.17195945.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17195945.s2.e0" e2="DDI-PubMed.17195945.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17195945.s2.e1" e2="DDI-PubMed.17195945.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17195945.s2.e1" e2="DDI-PubMed.17195945.s2.e2" /></sentence><sentence text=" We conducted a study to identify a safe dose and potential drug-drug interactions of this combination" /><sentence text="" /><sentence text="This was an open-label phase I dose escalation trial" /><sentence text=" Irinotecan was given as a 30 min infusion on days 1 and 8, and capecitabine on days 1-14 of a 21-day cycle"><entity charOffset="1-11" id="DDI-PubMed.17195945.s6.e0" text="Irinotecan" /><entity charOffset="64-76" id="DDI-PubMed.17195945.s6.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.17195945.s6.e0" e2="DDI-PubMed.17195945.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17195945.s6.e0" e2="DDI-PubMed.17195945.s6.e1" /></sentence><sentence text=" Plasma for pharmacokinetic analyses was drawn on days 1 and 8" /><sentence text="" /><sentence text="Forty-seven patients with advanced solid tumors received 202 cycles of chemotherapy in 6 dose cohorts" /><sentence text=" At the highest dose tested, 1 of 3 patients developed fatal neutropenia and gram-negative sepsis" /><sentence text=" At dose level 5 (100/2000), 2 of 28 patients developed cycle 1 DLT-grade 3 diarrhea/vomiting, and grade 3 diarrhea" /><sentence text=" Responses were observed in 9 of 35 (5 of 9 ovarian cancer) evaluable patients" /><sentence text=" The AUC((0-last)) of irinotecan, SN-38G, and APC were similar on days 1 and 8"><entity charOffset="22-32" id="DDI-PubMed.17195945.s13.e0" text="irinotecan" /><entity charOffset="34-40" id="DDI-PubMed.17195945.s13.e1" text="SN-38G" /><pair ddi="false" e1="DDI-PubMed.17195945.s13.e0" e2="DDI-PubMed.17195945.s13.e0" /><pair ddi="false" e1="DDI-PubMed.17195945.s13.e0" e2="DDI-PubMed.17195945.s13.e1" /></sentence><sentence text=" However, SN-38 T(max) was longer on Day 8 (0" /><sentence text="88 h vs" /><sentence text=" 1" /><sentence text="23 h, p = 0" /><sentence text="012)" /><sentence text=" While SN-38 AUC((0-last)) was lower on day 8 by 35%, this was not statistically significant (p = 0" /><sentence text="123)" /><sentence text="" /><sentence text="Capecitabine results in a significantly delayed conversion of irinotecan to SN-38, suggesting drug-drug interaction at the level of CES"><entity charOffset="0-12" id="DDI-PubMed.17195945.s22.e0" text="Capecitabine" /><entity charOffset="62-72" id="DDI-PubMed.17195945.s22.e1" text="irinotecan" /><entity charOffset="76-81" id="DDI-PubMed.17195945.s22.e2" text="SN-38" /><pair ddi="false" e1="DDI-PubMed.17195945.s22.e0" e2="DDI-PubMed.17195945.s22.e0" /><pair ddi="false" e1="DDI-PubMed.17195945.s22.e0" e2="DDI-PubMed.17195945.s22.e1" /><pair ddi="false" e1="DDI-PubMed.17195945.s22.e0" e2="DDI-PubMed.17195945.s22.e2" /><pair ddi="false" e1="DDI-PubMed.17195945.s22.e1" e2="DDI-PubMed.17195945.s22.e1" /><pair ddi="false" e1="DDI-PubMed.17195945.s22.e1" e2="DDI-PubMed.17195945.s22.e2" /></sentence><sentence text=" This suggests caution should be used when irinotecan is combined with substrates of CES, and warrants further study"><entity charOffset="43-53" id="DDI-PubMed.17195945.s23.e0" text="irinotecan" /></sentence><sentence text=" The combination of irinotecan and capecitabine is safe and well tolerated at 100/2000, and warrants further evaluation in ovarian and breast cancer"><entity charOffset="20-30" id="DDI-PubMed.17195945.s24.e0" text="irinotecan" /><entity charOffset="35-47" id="DDI-PubMed.17195945.s24.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.17195945.s24.e0" e2="DDI-PubMed.17195945.s24.e0" /><pair ddi="false" e1="DDI-PubMed.17195945.s24.e0" e2="DDI-PubMed.17195945.s24.e1" /></sentence><sentence text="" /></document>